drugset / Trial / NCT01174173

Ranolazine and Pulmonary Hypertension

NCT01174173

Phase 3 Completed 11 enrolled Northwestern University Gilead Sciences · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine if the medication, ranolazine (study drug), can help improve blood flow to your heart, increase your exercise capacity and improve your quality of life (QOL). For this study, you will be asked to perform several tests in order to determine if your heart function, exercise capacity, chest pain and QOL have improved after 3 months of treatment with ranolazine. Ranolazine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of angina.

Timeline

Start
2010-06
Primary completion
2014-01
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranolazine Small molecule 1000 mg Oral